** Shares of drugmaker United Therapeutics UTHR.O down 3.5% at $345 premarket
** Co posts quarterly adj profit of $6.19 per share, missing analysts' estimates of $6.31 per share, according to data compiled by LSEG
** However, co's Q4 revenue came in at $735.9 million on sales of its lung disorder inhaled-drug Tyvaso, slightly above estimates of $734.7 million
** Brokerage Leerink Partners says it appears that Tyvaso was not quite able to buck seasonal trends this quarter unlike a year ago
** The stock has risen ~60% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。